SEATTLE, Dec. 3, 2013 /PRNewswire/ -- Adaptive Biotechnologies, the pioneer of Next Generation Sequencing (NGS) of the adaptive immune system, and its collaborators will present data demonstrating how immunosequencing can inform survival in patients with blood cancers at the American Society of Hematology (ASH) meeting from December 7-10, 2013.
Immunosequencing is an emerging field where NGS technology is specifically tailored to sequence T and B cell receptors, enabling an in-depth characterization of the adaptive immune response.
clonoSEQTM, is a CLIA-certified immunosequencing diagnostic used to monitor Minimal Residual Disease (MRD), the cancerous cells remaining after treatment, in patients with T and B cell malignancies. The technology tracks a single clone that acts as a genetic "tag" of a leukemia or lymphoma. Flow cytometry is the current standard for tracking MRD, but the technique can be inaccurate and difficult to standardize.
At ASH, data will be presented that establishes a correlation between greater sensitivity of detection of rare clones using clonoSEQ and survival in patients with blood cancers. "clonoSEQ is the first sequencing-based diagnostic to demonstrate a significant improvement compared to flow cytometry. These data show we can better predict relapse and make informed clinical decisions to improve patient care," says Dr. Harlan Robins, Scientific Founder of Adaptive Biotechnologies.
immunoSEQTM, Adaptive's research-based immunosequencing assay, is being used extensively to monitor the immune repertoire over time after transplantation. At ASH, Adaptive and its collaborators will present data demonstrating a survival benefit due to a decreased risk of infection from the reconstitution of a diverse
|SOURCE Adaptive Biotechnologies Corporation|
Copyright©2012 PR Newswire.
All rights reserved